Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Howard Frederick who wrote (1121)	10/16/1998 9:55:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

For followers of MOGN, I'd advise calling IR at the company and getting the number to call and listen to the recording of yesterday's conference call. IMO, the comments made regarding the progress of MGI 114 have fundamentally shifted the balance of this investment from Salagen with a cancer drug possibility, to a cancer drug probability with Salagen as a backup. That is a big positive shift in the potential of the of the MOGN investment. If anyone is interested, call the company today because the recording can only be heard through 8:00 EDT tonight. For those who do listen, I'd like to hear your comments. David